Delivery Order SPE2DB24D9144-SPE2DB25FCMWL
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $17,245.40 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units). This firm fixed-price delivery order, executed on September 2, 2025, with an ultimate completion date of September 3, 2025, carries no set-aside designation. The award leverages DMS Pharmaceutical Group's existing Indefinite Delivery...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $8,622.72 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of 120 count bottles of Xtandi 40 mg capsules. The award was issued on September 8, 2025, with an ultimate completion date of September 9, 2025, and carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $12,934.05 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (quantity: 120). This firm fixed-price delivery order, issued on July 21, 2025, with an ultimate completion date of July 22, 2025, represents a continuation of the ongoing pharmaceutical supply relationship between the agency and the vendor. The award carries no...
- The Defense Logistics Agency awarded a delivery order valued at $65,695.52 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg tablets (120 count). The award, issued on August 25, 2025, with an ultimate completion date of August 26, 2025, utilizes firm fixed-price pricing with no set-aside designation. This delivery order falls under DMS Pharmaceutical Group's larger single-award Indefinite...
- The Defense Logistics Agency awarded a $8,339.18 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. on May 30, 2025, for the supply of Xtandi 80 mg tablets (60-count units). The award, effective through June 2, 2025, carries no set-aside designation. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will fulfill this order from its Park Ridge location. The company has been registered in the System for Award...
- The Defense Logistics Agency awarded a delivery order valued at $8,339.18 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 80 mg tablets (60-count units). The contract, issued on July 11, 2025, with an ultimate completion date of July 14, 2025, operates under a firm fixed-price structure with no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite...
- The Defense Logistics Agency awarded a $267,357.79 delivery order to DMS Pharmaceutical Group Inc. for the supply of Xtandi 40 mg capsules (120-count units) with a completion date of September 29, 2025. This firm fixed-price delivery order was issued without a set-aside designation, allowing the woman-owned small business based in Park Ridge, Illinois to compete directly in the federal pharmaceutical procurement market. The award leverages DMS Pharmaceutical Group's established capability as a...
- The Defense Logistics Agency awarded a delivery order valued at $12,508.77 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 80 mg tablets (60-count units). This firm fixed-price delivery order, issued on August 25, 2025, with an ultimate completion date of August 26, 2025, represents a procurement action under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA valued at...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,934.05 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units). The contract, effective August 12, 2025 with completion by August 13, 2025, is structured as a firm fixed-price delivery order with no set-aside designation. This award represents a single transaction under DMS Pharmaceutical Group's larger...
- The Defense Logistics Agency awarded a delivery order valued at $8,339.18 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg tablets (120-count units). The award, issued on August 29, 2025, with an ultimate completion date of September 2, 2025, utilizes a firm fixed-price contract type with no set-aside designation. This delivery order falls under DMS Pharmaceutical Group's larger Indefinite...
- SPE2DB24D9144Indefinite Delivery Contract
- SPE2DB24D9144-SPE2DB25FCMWLDelivery Order
The Defense Logistics Agency awarded a $12,650.53 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 60 tablets of Xtandi 80 mg. The delivery order, issued on July 25, 2025, with an ultimate completion date of July 28, 2025, carries no set-aside designation. This award is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA under the SPE2DB program, a $499,999,999 single-award vehicle valid through November 2026 that enables the agency to procure a comprehensive range of pharmaceutical products supporting military health facilities worldwide. Xtandi (enzalutamide) is a prescription oncology medication used in the treatment of prostate cancer, reflecting DLA's continued demand for specialized pharmaceutical products to support Department of Defense healthcare operations globally. DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain through its core business of distributing branded and generic prescription drugs, biologics, and medical consumables to military and federal healthcare facilities. The company's robust contract portfolio with DLA demonstrates its capability to reliably deliver specialized medications and medical supplies across diverse product categories to support the medical readiness of the armed forces.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $12.7k | 7/25/25 |